1. Medtech Insight
  2. >>Business
  3. >>Strategy

Philips Agrees Terms Of US Consent Decree, Remains Bullish On 2024

CEO proclaims light at the end of the tunnel of Respironics recalls

 
• By Ashley Yeo

Royal Philips CEO Roy Jakobs updated investors on progress of the company’s operating plan 2023-25, US actions and litigation on the Respironics portfolio, patient safety, quality and the order book as it announced Q4 2023 revenues.

Dark tunnel with a road winding through to a light at the end
• Source: Shutterstock

After more than 18 months of discussions, Royal Philips announced on 29 January that it has agreed with the US Department of Justice (DoJ) and Food and Drug Administration (FDA) the terms of the consent decree detailing how the company must change its manufacturing in the wake of the Respironics, Inc. product recalls.

Two US recall notices in June 2021 centering around breathing technologies within the sleep and respiratory care (S&RC) portfolio were the start of what turned into an ongoing crisis management exercise for one of the world’s top ten medtech companies by revenues (2022 data)

More from Strategy

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.

Roche’s $50Bn Bet On US Manufacturing: Tariff Shield But Cash Flow Strain

 
• By Shubham Singh

New continuous glucose monitoring manufacturing site in Indiana is part of Roche’s plan to boost its US presence. Roche’s launch of Accu-Chek SmartGuide system last year with AI-powered prediction capabilities puts it as a key differentiator from competitors such as Abbott and Dexcom.

Analysts See Insulet’s Appointment Of Ashley McEvoy As CEO As A Positive Move

 
• By Marion Webb

Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 
• By Natasha Barrow

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.

More from Business